Two new changes to CMS' ACO Investment Model will help practices in rural areas gain more access to the benefits of accountable care organizations.
Two new changes to CMS’ ACO Investment Model will help practices in rural areas gain more access to the benefits of accountable care organizations (ACOs).
The modifications will allow ACOs currently participating in the Medicare Shared Savings Program to apply in the next application round, and will remove the criteria that requires rural ACOs have 10,000 or fewer assigned beneficiaries for ACOs that started in the program in 2015 (or will start in 2016).
“These two changes reflect the Innovation Center’s commitment to listening to suggestions and ensuring that demonstrations are widespread, including rural providers and smaller physician groups,” Patrick Conway, MD, deputy administrator of innovation and quality and chief medical officer of CMS, wrote in a blog post.
The ACO Investment Model will provide $114 million in upfront investments to up to 75 ACOs across the country. The model was developed to encourage new ACOs to form in rural and underserved areas. Providers in rural areas have felt it is tough for them to participate in the ACO program because of the high startup costs.
“Through the CMS Innovation Center, this initiative will provide upfront and ongoing investments in infrastructure and redesigned care process to help eligible ACOs continue to provide higher quality care,” wrote Dr Conway. “This will help increase the number of beneficiaries that can benefit from lower costs and improved health care through Medicare ACOs.”
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More